miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 18, 2026

Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider

View original at globenewswire.com
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The U.S. leads globally in orphan drug approvals for chromosomal conditions

    80% confidence

  • The U.S. Turner Syndrome Market size was valued at an estimated USD 0.52 Billion in 2025 and is projected to reach USD 0.96 Billion by 2033, growing at a CAGR of 8.12% over the forecast period 2026–2033

    80% confidence

  • The Asia-Pacific region is expected to grow at the highest CAGR of 9.43%

    80% confidence

  • Turner syndrome occurs in 1 out of every 2,500 female newborns

    80% confidence

  • North America dominated the Turner syndrome market in 2025 with a 37.70% revenue share

    80% confidence

  • A majority of Turner syndrome patients are unaware of their condition until they enter adolescence

    80% confidence

  • The Turner Syndrome Market was valued at USD 1.93 Billion in 2025 and is projected to reach USD 3.67 Billion by 2033, reflecting a compound annual growth rate (CAGR) of 8.39% from 2026 to 2033

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider — Source | Via News | es.VIA.NEWS